Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 4
1983 4
1984 3
1985 8
1986 10
1987 16
1988 14
1989 11
1990 23
1991 18
1992 25
1993 28
1994 30
1995 34
1996 19
1997 26
1998 36
1999 46
2000 49
2001 33
2002 30
2003 39
2004 41
2005 44
2006 41
2007 39
2008 31
2009 43
2010 57
2011 56
2012 49
2013 49
2014 50
2015 40
2016 54
2017 48
2018 47
2019 46
2020 25
Text availability
Article attribute
Article type
Publication date

Search Results

1,195 results
Results by year
Filters applied: . Clear all
Page 1
ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Lichtenstein GR, et al. Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. Am J Gastroenterol. 2018. PMID: 29610508
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. ...
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influe
Oral and upper gastrointestinal Crohn's disease.
Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Laube R, et al. J Gastroenterol Hepatol. 2018 Feb;33(2):355-364. doi: 10.1111/jgh.13866. J Gastroenterol Hepatol. 2018. PMID: 28708248 Review.
Crohn's disease is a heterogeneous, inflammatory condition that can affect any location of the gastrointestinal tract. Proximal gastrointestinal involvement occurs in 0.5-16% of patients, and it is usually diagnosed after recognition of intestinal disease
Crohn's disease is a heterogeneous, inflammatory condition that can affect any location of the gastrointestinal tract. Proxima
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. Doherty G, et al. J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101. J Crohns Colitis. 2018. PMID: 28981623 Free article. Review.
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and Crohn's Disease [CD]. For each major class of IBD medications [5-aminosalicyclates, immunomodulators, and biologic agents], used alone or in combination, th …
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and Crohn's Disease [CD]. F …
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Derwa Y, et al. Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203. Epub 2017 Jun 27. Aliment Pharmacol Ther. 2017. PMID: 28653751 Free article. Review.
BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis. ...Eligible randomised controlled trials (RCTs) recruited adults with UC or …
BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates distur …
Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V. Ma C, et al. Dig Dis Sci. 2018 Oct;63(10):2555-2563. doi: 10.1007/s10620-018-5181-6. Epub 2018 Jun 29. Dig Dis Sci. 2018. PMID: 29959726
BACKGROUND: Aminosalicylates are the most commonly prescribed therapy in Crohn's disease (CD), despite uncertainty in the evidence to support their efficacy. ...CONCLUSIONS: Physicians' beliefs about efficacy in subgroups of CD patients, safety, and patient preferen …
BACKGROUND: Aminosalicylates are the most commonly prescribed therapy in Crohn's disease (CD), despite uncertainty in the evid …
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG. Coward S, et al. Inflamm Bowel Dis. 2017 Mar;23(3):461-472. doi: 10.1097/MIB.0000000000001023. Inflamm Bowel Dis. 2017. PMID: 28146003 Corrected and republished. Review.
BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial. PURPOSE: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease
BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial. PURPOSE: To compare the induction of rem …
Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V. Ma C, et al. Aliment Pharmacol Ther. 2018 Jul;48(2):114-126. doi: 10.1111/apt.14821. Epub 2018 May 30. Aliment Pharmacol Ther. 2018. PMID: 29851091 Free article.
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. ...While a decline has been seen over time, 35% of CD patients …
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to …
Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.
Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. Guizzetti L, et al. J Crohns Colitis. 2018 Jan 24;12(2):167-177. doi: 10.1093/ecco-jcc/jjx130. J Crohns Colitis. 2018. PMID: 29028958 Free PMC article.
BACKGROUND AND AIMS: Crohn's disease-related complications account for a substantial proportion of inflammatory bowel disease-associated health care expenditure. ...These models could be used to guide Crohn's disease management. External validat …
BACKGROUND AND AIMS: Crohn's disease-related complications account for a substantial proportion of inflammatory bowel disea
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Ford AC, et al. Am J Gastroenterol. 2011 Apr;106(4):617-29. doi: 10.1038/ajg.2011.71. Epub 2011 Mar 15. Am J Gastroenterol. 2011. PMID: 21407190 Review.
OBJECTIVES: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Evidence for treatment with 5-aminosalicylic acid (5-ASA) drugs is conflicting. We conducted a systematic review and meta-analysis of randomized controll …
OBJECTIVES: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Evidence for treatment with …
Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis.
Iny O, Yanai H, Matalon S, Santo E, Shibolet O, Dotan I, Maharshak N. Iny O, et al. Isr Med Assoc J. 2018 Jan;20(1):25-29. Isr Med Assoc J. 2018. PMID: 29658203 Free article.
BACKGROUND: Up to 3.4% of Crohn's disease (CD) patients will be diagnosed with concomitant primary sclerosing cholangitis (PSC). ...Disease phenotype (according to the Montreal classification), demographics, and clinical data were compared in the two groups. …
BACKGROUND: Up to 3.4% of Crohn's disease (CD) patients will be diagnosed with concomitant primary sclerosing cholangitis (PSC …
1,195 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback